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Abstract Gingipain-R, the major arginine-specific proteinase
from Porphyromonas gingivalis, a causative agent of adult
periodontal disease, was found to cleave a model peptide
representing the cleavage site of proteinase-activated receptor-2
(PAR-2), a G-protein-coupled receptor found on the surface of
neutrophils. The bacterial proteinase was also shown to induce an
increase in the intracellular calcium concentration of enzyme-
treated neutrophils, most probably due to PAR-2 activation. This
response by neutrophils to gingipain-R may be a mechanism for
the development of inflammation associated with periodontal
disease.
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1. Introduction
Proteinase-activated receptor-2 (PAR-2) is a member of the
seven-transmembrane domain receptor family which couple to
G-proteins to produce intracellular signals leading to cellular
responses [1]. PAR-2 is expressed in a number of tissues, in-
cluding the gastrointestinal and respiratory tracts and skin,
where expression is primarily in the epidermal and smooth
muscle cells [1^10]. The receptor is also expressed by human
neutrophils and its stimulation leads to neutrophil activation
[11], which may contribute to a neutrophil-induced in£amma-
tory response. In order to evaluate the possible role of PAR-2
in in£ammation, however, it is necessary to identify physio-
logical and pathophysiological activators of this receptor,
after which it will be possible to determine under which con-
ditions activation of PAR-2 on neutrophils is likely to occur.
Cleavage of the PAR-2 extracellular domain after residue
arginine-36 produces a new N-terminus, which acts as a teth-
ered ligand that binds to the receptor and leads to its activa-
tion. A synthetic receptor agonist peptide (RAP) correspond-
ing to the tethered ligand is also able to activate the receptor.
However, the physiological activators of PAR-2 in most tis-
sues have not yet been identi¢ed, although trypsin has been
suggested to activate PAR-2 under physiological conditions in
the gastrointestinal tract [12]. In addition, tryptase may be
important in pathological conditions involving mast cell in¢l-
tration and/or degranulation [13,14].
Severe adult periodontitis is characterised by an acute in-
£ammatory response with neutrophil in¢ltration into the gin-
gival tissue, followed by the establishment of a chronic disease
state typi¢ed by extensive tissue degradation and eventual
bone erosion with loss of teeth [15]. It is known that Gram-
negative anaerobes are responsible for adult periodontitis and
the bacterium Porphyromonas gingivalis has been identi¢ed as
a major pathogen [16^19]. Proteinases produced by this or-
ganism are believed to play a critical role in the virulence of
the organism [17,20] and thus in the initiation and progression
of adult periodontitis.
Two types of cysteine proteinases, present in multiple
forms, are responsible for the so-called trypsin-like activity
of P. gingivalis [21]. Those speci¢c for arginyl-X bonds (50
and 95 kDa) [22] and that for lysyl-X bonds (105 kDa) [23]
have been puri¢ed and are referred to as gingipain-R and
gingipain-K, respectively. The proteolytic activity of these en-
zymes, which are associated with both the cell surface and the
vesicles of the bacterium [21], has been shown to have a pro-
found disruptive e¡ect on host systems, particularly those
controlling in£ammatory events. In addition, they have also
been demonstrated to decrease blood coagulation [24], en-
hance vascular permeability [25] and activate the complement
system [26], thus contributing to the in£ammation seen in
periodontal disease. Gingipain-R cleaves complement factor
C5 to yield C5a-like fragments with neutrophil chemoattrac-
tant activity [27]. The local production of these chemotactic
anaphylotoxins could be one mechanism for recruiting neu-
trophils into the in£amed tissue and for their subsequent ac-
tivation, with consequent degranulation and generation of
oxygen radicals at a¡ected sites [15]. Thus, the question to
be addressed is whether gingipain-R can act on receptors
such as PAR-2, expressed on the surface of neutrophils, and
thereby elicit intracellular signals.
2. Materials and methods
2.1. Materials
Bovine serum albumin (BSA), N-formyl-Met-Leu-Phe (fMLP), pol-
ymyxin B sulfate and L-cysteine were purchased from Sigma (Sydney,
Australia). Fura-2-AM was obtained from Molecular Probes (Eugene,
OR, USA). Percoll was purchased from Pharmacia (Sydney, Austral-
ia). The £uorescence quenched peptides Abz-Leu-Asp-Pro-Arg-Ser-
Phe-Leu-Leu-Lys(Dnp)-Asp-OH (PAR-1) and Abz-Ser-Lys-Gly-Arg-
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Ser-Leu-Ile-Gly-Lys(Dnp)-Asp-OH (PAR-2) were synthesised using
standard solid-phase 9-£uorenylmethyloxycarbonyl (Fmoc) chemistry
with an automated peptide synthesiser (Applied Biosystems, model
432A). They were puri¢ed using reverse-phase high performance
liquid chromatography and their structure was con¢rmed by mass
spectroscopy.
2.2. Gingipain-R puri¢cation
The 50 kDa form of gingipain-R was puri¢ed as described previ-
ously [22]. Enzyme was activated by treatment with 10 mM L-cysteine
at 37‡C, for 15 min, in 0.1 M Tris-HCl, 5 mM CaCl2, pH 7.4. Poly-
myxin B sulfate (100 Wg/ml) was routinely added to inhibit any cel-
lular stimulation by bacterial lipopolysaccharides.
2.3. Enzyme assays and measurement of kinetic constants
Experiments were carried out in 0.1 M HEPES, 0.1 M NaCl, 10 mM
CaCl2, 0.2% (w/v) polyethylene glycol (Mr 6000), pH 7.4. The sub-
strate solution (0.5 ml) was allowed to equilibrate to 37‡C for 10 min,
enzyme solution was added, and enzyme activity monitored by con-
tinuously measuring the £uorescence (Vex = 325 nm; Vem = 414 nm
[10 nm slits]) in a Perkin Elmer LS-50B spectro£uorometer [28].
Lyophilised PAR-1 and PAR-2 peptides were resuspended in di-
methylformamide, and the concentration of the stock solution
(6.4 mM) determined spectrophotometrically, assuming an absorption
coe⁄cient of 104 M31 cm31 at 360 nm [28]. Fluorescence of peptide
products after exhaustive cleavage by trypsin was found to be propor-
tional to concentration. Accordingly, an increase in £uorescence could
be equated to the increase in concentration of the cleaved substrate,
allowing determination of the kinetic parameters, Km and kcat from an
analysis of initial velocities obtained at di¡erent substrate concentra-
tions.
2.4. Measurement of intracellular Ca2 + responses in isolated
neutrophils
Neutrophils were isolated by fractionation of freshly drawn human
blood from normal volunteers, using Percoll gradients as described
previously [29]. Preparations containing more than 95% neutrophils,
with eosinophils as the major contaminant, were suspended at a con-
centration of 10U106 cells/ml in extracellular medium (25 mM
HEPES, pH 7.3, 121 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2,
5 mM CaCl2, 6 mM NaHCO3 and 5.5 mM glucose) containing
0.2% w/v BSA.
Neutrophils were loaded with Fura-2 at room temperature as de-
scribed previously [29]. Prior to £uorescence measurements, cells were
centrifuged, resuspended in extracellular medium (without BSA) at a
concentration of 3U106 cells/ml and then maintained at 37‡C in
stirred cuvettes throughout the experiment. The ratio of the Fura-2
£uorescence at 510 nm after excitation at 340 and 380 nm was moni-
tored using a Perkin Elmer LS-50B spectro£uorimeter. After initial
baseline recording, trypsin, gingipain-R (50 kDa) and agonist peptide
(RAP) were added to the cells, and the ratio of the £uorescence at the
two excitation wavelengths measured, which is proportional to the
[Ca2]i.
3. Results and discussion
A synthetic peptide, Abz-Ser-Lys-Gly-Arg-Ser-Leu-Ile-Gly-
Lys(Dnp)-Asp-OH, which corresponds to the four amino
acids on either side of the cleavage site of human PAR-2
(residues 33^41 of human PAR-2), was evaluated for its ac-
curacy as a predictor of receptor cleavage. The Abz group
only £uoresces upon release of the Lys(Dnp) quenching group
following proteolytic cleavage. Thus, hydrolysis within the
PAR-2 activation sequence by a potential receptor activator
can initially be assessed in this manner. In order to test this
system, cleavage of the peptide was examined with trypsin and
thrombin, which are known to be activating and non-activat-
ing for the PAR-2 receptor, respectively. It was found that
trypsin cleaved the peptide at concentration as low as 0.1 nM,
while thrombin was incapable even at signi¢cantly higher lev-
els (0.1^100 nM). Trypsin exhibited a high a⁄nity for the
peptide as evidenced by a low Km value (Table 1), and cleaved
the peptide e⁄ciently, with a high kcat/Km value. This cleavage
by trypsin, but not thrombin, supports the hypothesis
that this peptide may be considered an e¡ective model for
determining the potential of a given proteinase to activate
PAR-2.
A novel potential pathophysiological activator of PAR-2,
gingipain-R, was then examined for its ability to hydrolyse the
PAR-2 peptide, prior to its being tested in cellular systems.
Gingipain-R at concentrations as low as 0.1 nM cleaved the
test peptide with very similar kinetics to trypsin (Table 1),
indicating that the enzyme has the potential to cleave within
the receptor itself. The speci¢city of gingipain-R for the PAR-
2 peptide was further indicated by its inability to cleave the
peptide representing the activation sequence of the related
receptor, PAR-1, Abz-Leu-Asp-Pro-Arg-Ser-Phe-Leu-Leu-
Lys(Dnp)-Asp-OH, using concentrations of enzyme of
1^50 nM, despite the fact that the peptide also contains an
arginine residue. This is consistent with previous results which
showed that gingipain-R was unable to activate PAR-1 on
platelets [30].
Cleavage of the synthetic PAR-2 peptide by trypsin and
gingipain-R proceeded according to similar kinetic constants,
suggesting that cell-surface PAR-2 may be cleaved by gingi-
pain-R. We, therefore, addressed this question by monitoring
the increase in intracellular calcium levels of neutrophils in
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Table 1
Kinetic parameters of the cleavage of a synthetic peptide corre-
sponding to activation sequence of PAR-2
Enzyme Km (WM) kcat (s31) kcat/Km (WM s31)
Trypsin 5.5 86 15.6
Gingipain-R 3.0 50.0 16.6
Fig. 1. The [Ca2]i response of neutrophils to di¡erent concentrations of gingipain-R and trypsin. Neutrophils (from donor MB) were loaded
with Fura-2 and stimulated with gingipain-R and trypsin. The increases in [Ca2]i at di¡erent proteinase concentrations represent the mean þ
S.E.M. derived from three traces similar to those shown in Fig. 2.
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response to gingipain-R. Neutrophils are a good model for
examining this process as they play a role in adult periodon-
titis and PAR-2 is the only proteinase-activated receptor
known to be expressed on the surface of these phagocytic cells
[29].
Neutrophils from several donors were individually tested
for a [Ca2]i response to gingipain-R, trypsin and the receptor
agonist peptide (RAP) (Table 2). All samples showed an in-
crease in [Ca2]i in response to RAP treatment. The magni-
tude of the [Ca2]i response varied between individuals, con-
¢rming results described elsewhere [11], where it was observed
that the neutrophils of all donors express PAR-2, including
some that did not respond to trypsin.
Gingipain-R induced a dose-dependent increase in [Ca2]i
in neutrophils. The concentration dependence of such an in-
crease using neutrophils from a single donor is shown in Fig.
1, yielding an enzyme concentration inducing half the maxi-
mal response (EC50) of 49.8 þ 3.9 nM and 39.2 þ 3.9 nM for
receptor activation by gingipain-R and trypsin, respectively.
As with the RAP activation, the magnitude of the [Ca2]i
increase caused by gingipain-R varied between donors, but
the bacterial enzyme induced an increase in [Ca2]i only in
neutrophils from donors that, in parallel, also exhibited a
trypsin-induced increase in intracellular calcium (eight of the
12 donors) (Table 2). The variation in response and the lack
of response to enzyme activation in certain donors is again in
agreement with previous observations [11]. Neutrophils which
did not respond to either proteinase did respond to the fMLP
peptide, suggesting that G-protein-coupled receptor signalling
pathways in otherwise non-responsive neutrophils were intact.
Proteinase-activated receptors undergo rapid desensitisation
after a short period of activation by an enzyme agonist. Since
exposure of cells to trypsin desensitises [Ca2]i responses to
subsequent challenges with trypsin due to cleavage of PAR-2
(Fig. 2A) [31], experiments were carried out using the [Ca2]i
mobilisation assay in order to determine if gingipain-R and
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Table 2
Intracellular calcium £ux in response to various agonists in neutrophils from 12 donors
Donor Fluorescence ratio 340/380 nm
GP-R 200 nM Trypsin 200 nM RAP 300 WM fMLP 10 nM
1 0.50 0.41 0.45 0.80
2 0.37 0.35 0.40 0.87
3 0.30 0.12 0.42 1.39
4 0.23 0.28 0.32 0.50
5 0.22 0.18 0.28 0.75
6 0.18 0.12 0.48 0.68
7 0.09 0.10 0.50 0.81
8 0.08 0.13 0.20 0.50
9 0 0 0.23 1.05
10 0 0 nd 0.50
11 0 0 nd 0.30
12 0 0 nd 0.50
nd, not determined.
Fig. 2. E¡ects of desensitisation on [Ca2]i responses in neutrophils. Cells were exposed to (A) 200 nM trypsin, then challenged with 200 nM
trypsin, (B) 200 nM trypsin, then challenged with 200 nM gingipain-R, (C) 200 nM gingipain-R, then challenged with 200 nM trypsin and (D)
200 nM gingipain-R, then challenged with 200 nM gingipain-R and followed by 10 nM fMLP peptide. This ¢gure shows the desensitisation ef-
fects for one of the eight donors in whom these e¡ects were observed.
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trypsin were activating the same receptor. When neutrophils
were initially activated with gingipain-R, a secondary response
to this enzyme was virtually eliminated (Fig. 2D). Exposure of
neutrophils to trypsin also desensitised the [Ca2]i response to
a second challenge with gingipain-R (Fig. 2B). Similarly, ex-
posure of neutrophils to gingipain-R desensitised the response
to a second challenge by trypsin (Fig. 2C). The fMLP peptide
caused an increase in [Ca2]i in gingipain-R-treated neutro-
phils (Fig. 2D), indicating that depletion of intracellular cal-
cium is not the mechanism of desensitisation. Since PAR-2 is
a known proteinase-activated receptor on neutrophils which
can be cleaved by trypsin [15,29], these results strongly suggest
that trypsin and gingipain-R activate a common receptor on
neutrophils, i.e. PAR-2.
It has been shown that stimulation of PAR-2 by RAP leads
to neutrophil activation as indicated by an increase in the
expression of CD11b and shape changes [11]. PAR-2 activa-
tion in a human keratinocyte cell line has been shown to
induce the expression of granulocyte-macrophage colony-
stimulating factor and interleukin-6, both factors which are
known to participate in in£ammatory processes [32]. Neutro-
phil activation by gingipain-R acting via PAR-2 may there-
fore exacerbate the in£ammation seen in periodontal disease
and thus the results presented here raise the possibility that
P. gingivalis, through its proteinase gingipain-R, makes use of
host cell receptors to exacerbate bacterially induced tissue
destruction.
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